The Relationship between Endothelial Dysfunction and Endothelial Cell Markers in Peripheral Arterial Disease

Kimihiro Igari*, Toshifumi Kudo, Takahiro Toyofuku, Yoshinori Inoue

Department of Surgery, Division of Vascular and Endovascular Surgery, Tokyo Medical and Dental University, Tokyo, Japan

* igari.srg1@tmd.ac.jp

Abstract

Introduction
The endothelial function plays key roles in both promoting and protecting against atherosclerotic disease. Several methods, including peripheral arterial tonometry (PAT), have been reported to be useful for investigating endothelial dysfunction. Furthermore, the level of thrombomodulin (TM) is assumed to reflect the endothelial dysfunction. In the present study, we investigated endothelial dysfunction in patients with peripheral arterial disease (PAD) by measuring their TM levels, and evaluated the correlation between TM and various parameters.

Materials and Methods
We measured the TM levels and performed PAT in 17 patients with PAD. We also recorded the patients' demographic information, including comorbidities, and investigated their hemodynamic status by measuring the ankle brachial pressure index (ABI). The PAT results were used to calculate the reactive hyperemia index (RHI), which reflected the patients' level of endothelial dysfunction.

Results
The RHI and ABI values and the serum level of creatinine were found to be significantly correlated with the TM level (P = 0.040, 0.041 and 0.005, respectively). After setting an RHI value of 1.67 as the cut-off, the patients with RHI values of <1.67 were found to have significantly higher TM levels (median, 20.3 U/mL) than the patients with RHI values of ≥1.67 (median, 13.7 U/mL) (P = 0.023).

Conclusions
The degree of endothelial dysfunction, as calculated by the TM level, might influence the prognostic value of the RHI, which is determined by PAT. The measurement of the TM level and PAT might both be useful methods of measuring endothelial dysfunction in patients with PAD.
Introduction

The endothelium is a delicate monolayer of cells with whole blood vessels that plays an important role in the initiation and development of atherosclerotic diseases. Although the function of the endothelium is to protect against atherosclerotic disease, endothelial dysfunction can actually promote atherosclerotic diseases [1]. Furthermore, endothelial dysfunction plays key roles in vascular inflammation and thrombosis [2]. Thus, the measurement of the endothelial function has shown varying degrees of effectiveness in the stratification of atherosclerotic diseases [3].

Endothelial dysfunction has been established as an important early event in the pathogenesis of atherosclerosis, with changes in endothelial function occurring well before the onset of clinically apparent cardiovascular disease [4]. We can now evaluate the endothelial function by several non-invasive tests. Peripheral arterial tonometry (PAT) evaluates the digital pulse amplitude, which is a measurement of pulsatile volume changes [5]. Celermajer reported that PAT yields relevant predictive and prognostic data that reflect endothelial function [6]. PAT could therefore be used to assess changes in blood flow, which reflects the endothelial function—especially the microvascular endothelial function [7].

Furthermore, several plasma markers have shown a significant correlation with endothelial dysfunction [8, 9]. Thrombomodulin (TM), an endothelial membrane glycoprotein, plays a promising role in the protein C anticoagulant pathway. When TM, which is a thrombin receptor, is activated by thrombin, it facilitates protein C activation [10]. Some divided TM fragments exist in systemic circulation as soluble TM. Some studies have reported that the concentration of TM is associated with peripheral arterial disease (PAD) [11], and reflects the level of endothelial damage [12]. Sernau et al. concluded that TM is a marker of microvascular endothelial cell damage [13].

We conducted a pilot study to evaluate endothelial dysfunction in PAD patients by measuring their TM levels and performing PAT, and investigated the relationships between the TM level (as a measure of endothelial dysfunction) and various parameters.

Material and Methods

Patient selection

We recruited consecutive 17 patients with PAD who had undergone PAT and whose serum TM levels had been measured at an outpatient clinic at Tokyo Medical and Dental University Hospital between May 2014 and March 2015. PAD was diagnosed based on the presence of > 50% vessel stenosis due to lesions in the lower limbs. We mainly assessed the vessel stenosis by computed tomography angiography. In the cases with contraindication of using contrast media, such as chronic kidney disease and allergy, we evaluated the stenosis using magnetic resonance angiography and/or duplex ultrasound sonography. All of the patients provided their written informed consent, then we enrolled. This study was approved by the ethics committee of Tokyo Medical and Dental University (No. 701), and we reviewed the patients’ medical examinations and records. In the present study, we excluded patients who had recently undergone interventions for PAD or coronary artery disease (CAD) (< 6 months), and patients with a recent history (< 3 months) of myocardial infarction, unstable angina, decompensated heart failure, or cerebrovascular disease (CVD). We also excluded the patients with systemic inflammatory and malignant diseases. The patients’ medical records were reviewed as described below, and we investigated the patients’ demographics, medications and medical histories using a questionnaire. Hypertension was defined as a systolic blood pressure of > 130 mmHg, a diastolic blood pressure of > 80 mmHg or a history of treatment for hypertension.
Dyslipidemia was defined as a serum low-density lipoprotein cholesterol level of > 140 mg/dL, a high-density lipoprotein cholesterol level of < 40 mg/dL, a triglyceride level of > 150 mg/dL or a history of treatment for dyslipidemia. CAD was defined as the presence of angina pectoris, myocardial infarction or both, on coronary angiography, or based on the history of the patient having undergone coronary artery revascularization. CVD was defined as a history of stroke, transient ischemic attack, carotid artery revascularization or cerebral hemorrhage. Diabetes mellitus was defined as having a fasting blood glucose level of > 126 mg/dL, a hemoglobin A1c concentration of > 6.5%, or the use of antidiabetic drugs. The severity of PAD was assessed by the measurement of the ankle brachial pressure index (ABI). The ABI was measured using a VasoGuard P84™ system (SciMed Ltd., Bristol, UK). We measured the systolic blood pressure on both sides of the brachial arteries in the upper limbs. In the lower extremities, both the posterior tibial arterial and dorsal pedis arterial pressures were measured if available. The ABI value was calculated based on the higher systolic blood pressure of the lower limbs divided by the higher brachial systolic blood pressure.

**Endothelial function test**

To assess the endothelial function, pulse wave amplitude was assessed before and during reactive hyperemia, which is induced by occluding blood flow of brachial artery using inflatable cuff. The calculated index (reactive hyperemia index; RHI) between the flow in the upper arm with reactive hyperemia and the control upper arm represents a measure of the endothelial function [14]. We used the EndoPAT 2000 device (Itamar Medical Ltd., Caesarea, Israel), which is capable of determining the RHI, to measure the endothelial function. Patients refrained from smoking, drinking caffeine-containing beverages and eating food in the 12 hours before prior to PAT. The patients also stopped taking all drugs for 12 hours before the study. For PAT, the patients were placed in a supine position with a configured finger probe on the index finger of each hand, and a pressure cuff was placed on one upper arm, in a quiet room with a constant temperature of 20˚C. The PAT signals from both fingers were continuously recorded during the 10-minute baseline period. The blood pressure cuff on the examined upper arm was then inflated to suprasystolic pressure for 5 minutes. The inflated cuff was then deflated, and the recording of the PAT signal continued for 10 minutes. Pressure changes reflecting the pulse amplitude both before the inflation of the cuff and after the deflation of the cuff, were transmitted to a computer, and the RHI was automatically calculated [15].

**Laboratory measurement**

After the patients had fasted for at least 12 hours, non-traumatic venipuncture was performed in a superficial vein of upper limb to collect blood samples. Complete blood cell counts were measured and biochemistry tests were performed using standard laboratory methods. Several plasma aliquots were withdrawn (from the blood samples) after centrifugation in a floor-standing centrifuge for 20 minutes at 2,500 rpm. The samples were stored until use at -80˚C. We also measured the serum levels of TM using a Thrombomodulin Enzyme Immunoassay kit (SRL, Inc., Tokyo, Japan).

**Statistical analysis**

Categorical variables are expressed as frequencies and percentages, and continuous variables are expressed as median and interquartile range (IQR). The statistical significance was assessed using the Mann-Whitney U test for continuous variables. Correlations between the TM level and several parameters were assessed using Spearman’s correlation coefficient. P values
of < 0.05 were considered to indicate statistical significance. The statistical analyses were performed using the Stat View software program (version 5, Abacus Concept Inc., Berkley, CA).

Results

Patient demographics

We evaluated 17 (14 males and 3 females) PAD patients in the present study. The median age was 71 years (IQR, 66–80), and the median body mass index was 22.0 kg/m$^2$ (IQR, 20.8–22.8). The documented comorbidities included hypertension (82.4%), smoking history (70.6%), dyslipidemia (70.6%), DM (70.6%), CVD (29.4%) and CAD (17.6%). Ten patients (58.8%) were taking with Ca-blockers, and 3 patients (17.6%) were taking β-blockers. The laboratory test findings are shown in Table 1. With regard to the hemodynamic parameters, the median ABI

Table 1. Patients characteristics.

| Variables                                | Subjects (n = 17) |
|------------------------------------------|------------------|
| Age (years), median, IQR*                | 71, 66–80        |
| Gender (Male / Female)                   | 14 / 3           |
| Body mass index (kg/m$^2$), median, IQR* | 22.0, 20.8–22.8  |

| Comorbidities                           |                  |
|------------------------------------------|------------------|
| Smoking history, number, percentage     | 12, 70.6%        |
| Hypertension, number, percentage        | 14, 82.4%        |
| Dyslipidemia, number, percentage        | 12, 70.6%        |
| Coronary artery disease, number, percentage | 3, 17.6%      |
| Cerebrovascular disease, number, percentage | 5, 29.4%       |
| Diabetes mellitus, number, percentage   | 12, 70.6%        |

| Medications                              |                  |
|------------------------------------------|------------------|
| Ca-blocker, number, percentage           | 10, 58.8%        |
| β-blocker, number, percentage            | 3, 17.6%         |

| Hemodynamic parameters                   |                  |
|------------------------------------------|------------------|
| Ankle brachial pressure index, median, IQR* | 0.82, 0.63–0.98 |
| Reactive hyperemia index, median, IQR*   | 1.46, 1.36–1.68  |

| Laboratory findings                      |                  |
|------------------------------------------|------------------|
| White blood cell (/μl), median, IQR*     | 6400, 5700–7300  |
| Hemoglobin (g/dl), median, IQR*          | 12.8, 12.2–14.7  |
| Platelet (x10$^3$/μl), median, IQR*      | 21.6, 18.9–25.2  |
| Prothrombin time (%), median, IQR*       | 101.8, 91.7–107.3|
| Activated partial thromboplastin time (sec), median, IQR* | 28.4, 27–30.1  |
| Fibrinogen (mg/dl), median, IQR*         | 304, 269–317     |
| D-Dimer (μg/ml), median, IQR*            | 1.06, 0.78–2.10  |
| Creatinine (mg/dl), median, IQR*         | 0.92, 0.78–1.44  |
| Total cholesterol (mg/dl), median, IQR*   | 193, 160–205     |
| Triglycerides (mg/dl), median, IQR*      | 92.71–205        |
| High-density lipoprotein (mg/dl), median, IQR* | 54, 48–67       |
| Low-density lipoprotein (mg/dl), median, IQR* | 116, 101–121    |
| Hemoglobin A1c (%), median, IQR*         | 6.75, 6.45–7.05  |
| C-reactive protein (mg/dl), median, IQR*  | 0.08, 0.05–0.17  |
| Thrombomodulin (FU/ml)                   | 18.5, 13.7–21.3  |

* IQR, interquartile range.

doi:10.1371/journal.pone.0166840.t001
level was 0.82 (IQR, 0.63–0.98), and the median RHI value (measured by PAT) was 1.46 (IQR, 1.36–1.68) (Table 1).

Correlations between TM and other parameters
The correlations between TM and each of the parameters are shown in Table 2. None of the evaluated parameters, except the serum creatinine level and the RHI and ABI values, showed any significant correlation with the TM level. The TM level was significantly correlated with the serum creatinine level ($\rho = 0.701$, $P = 0.005$), and the RHI ($\rho = -0.512$, $P = 0.040$) and ABI ($\rho = -0.510$, $P = 0.041$) values. However, we evaluated the statistical significance by multiple testing with Bonferroni correction in which $P$ values of $< 0.0016$ was considered to indicate statistical significance, then, serum creatinine, RHI and ABI did not show the statistical significant association with TM.

The relationship between the TM level and the RHI and ABI values (S1 Table)
An RHI value of $< 1.67$ was defined as cut-off value of endothelial dysfunction [1]. We therefore divided the study population into two groups of RHI $< 1.67$ (n = 12) and RHI $\geq 1.67$.

Table 2. The correlations between thrombomodulin and various parameters.

| Variables                  | Correlation coefficient | P-value |
|----------------------------|-------------------------|---------|
| Age                        | 0.074                   | 0.769   |
| Gender                     | 0.105                   | 0.675   |
| Body mass index            | 0.482                   | 0.054   |
| Comorbidities              |                         |         |
| Smoking history            | 0.251                   | 0.316   |
| Hypertension               | 0.188                   | 0.452   |
| Dyslipidemia               | 0.398                   | 0.144   |
| Coronary artery disease    | 0.469                   | 0.061   |
| Cerebrovascular disease    | 0.230                   | 0.358   |
| Diabetes mellitus          | 0.240                   | 0.337   |
| Medications                |                         |         |
| Ca-blocker                 | 0.001                   | 0.998   |
| $\beta$-blocker            | -0.093                  | 0.710   |
| Hemodynamical parameters   |                         |         |
| Ankle brachial pressure index | -0.510              | 0.041   |
| Reactive hyperemia index   | -0.512                  | 0.040   |
| Laboratory findings        |                         |         |
| White blood cell           | 0.213                   | 0.395   |
| Hemoglobin                 | -0.202                  | 0.420   |
| Platelet                   | -0.161                  | 0.521   |
| Prothrombin time           | -0.425                  | 0.090   |
| Activated partial thromboplastin time | 0.280 | 0.263   |
| Fibrinogen                 | 0.415                   | 0.098   |
| D-Dimer                    | -0.163                  | 0.590   |
| Creatinine                 | 0.701                   | 0.005   |
| Total cholesterol          | 0.014                   | 0.956   |
| Triglycerides              | -0.226                  | 0.382   |
| High-density lipoprotein   | -0.124                  | 0.642   |
| Low-density lipoprotein    | 0.404                   | 0.131   |
| Hemoglobin A1c             | -0.276                  | 0.284   |
| C-reactive protein         | 0.152                   | 0.543   |

doi:10.1371/journal.pone.0166840.t002
(n = 5) according to their RHI values. The patients with RHI values of < 1.67 showed a significantly higher TM level (median, 20.3 U/mL) than patients with RHI values of ≥ 1.67 (median, 13.7 U/mL) (P = 0.023). Furthermore, we divided the patients who underwent a PAD test based on their ABI values of ≤ 0.90 (n = 11) and ABI > 0.90 (n = 6). The group patients with ABI values of > 0.90 showed a significantly lower TM level (median, 13.2 U/mL) than the patients with ABI values of ≤ 0.90 (median, 20.6 U/mL) (P = 0.004) (Table 3).

Discussion

TM is an endothelial membrane receptor for thrombin, which is an essential part of the protein C anticoagulant pathway. It has a large extracellular portion, in which most of its activity takes place [16]. Furthermore, some investigators have reported that TM may function as an antithrombotic and atheroprotective mediator [17]. Several factors have been reported to be correlated with the TM level, including inflammatory disease [18], systemic disease [19], and malignant disease [20]. Some types of atherosclerotic disease, including CAD [21], CVD [22] and aneurysmal disease [23], have been reported to be positively associated with TM. Furthermore, some studies have reported a positive association between TM and PAD [11, 24]. In line with the results of these previous studies, we showed a significant correlation between the TM level and the severity of PAD, as measured by ABI value; thus, the TM level might reflect the severity of PAD. We also found a significant correlation between the serum levels of TM and creatinine (ρ = 0.701, P = 0.005). Bao et al. [25] reported that serum TM level was significantly correlated with serum creatinine level (r = 0.778, P < 0.001), and TM was thought to play a key role in the development of chronic kidney disease.

We found a significant correlation between the TM level and the RHI value in the present study. The difference in blood flow, as measured by PAT, reflects microvascular dysfunction and might be useful for evaluating endothelial dysfunction at the microcirculation level [7]. Several studies have reported a correlation between the TM level and PAD [24, 26]. Furthermore, the TM concentration could reflect the presence of microvascular complications and the severity of endothelial cell injury [27]. The present study found a significant correlation between the TM level and the RHI value (as measured by PAT), which have previously been reported as markers of microvascular endothelial dysfunction. To the best of our knowledge, this is the first study to report a positive association between the endothelial dysfunction, as measured by PAT and TM elevation.

The present study is associated with several limitations. First, the small sample size might have affected the statistical significance. We should therefore conduct a further study to confirm the significance of the correlations in a larger population. Second, our study included the PAD patients with relatively mild symptoms. The presence of PAD patients with critical limb ischemia or asymptomatic PAD patients in our population might have affected our results.

Table 3. Relationship between thrombomodulin and reactive hyperemia index, ankle brachial pressure index.

| Variables (median, IQR*) | RHI° < 1.67 | RHI° ≥ 1.67 | P-value |
|--------------------------|-------------|-------------|---------|
| Thrombomodulin           |             |             |         |
| ABI≤ 0.90                | 13.2 (12.1–14.2) | 0.004       |
| ABI> 0.90                | 13.2 (12.1–14.2) | 0.004       |
| Thrombomodulin           |             |             |         |
| ABI≤ 0.90                | 13.2 (12.1–14.2) | 0.004       |
| ABI> 0.90                | 13.2 (12.1–14.2) | 0.004       |

* IQR, interquartile range
° RHI, reactive hyperemia
Δ ABI, ankle brachial pressure index.

doi:10.1371/journal.pone.0166840.t003
Despite the limitations of the present study, we demonstrated significant correlations between the TM level (a measurement of endothelial dysfunction) and the RHI, as measured by PAT.

**Conclusions**

We herein demonstrated that the TM level was significantly correlated with the RHI value, the ABI and the serum level of creatinine in PAD patients. Several factors might have affected our results. We should therefore perform a further study to confirm our findings. We used PAT as a novel method of evaluating the endothelial dysfunction of PAD patients. The results were confirmed based on the measurement of their TM levels, which showed the severity of endothelial dysfunction.

**Supporting Information**

S1 Table. Patients’ data of thrombomodulin and reactive hyperemia index, ankle brachial pressure index.

(DOCX)

**Author Contributions**

Conceptualization: KI YI.
Formal analysis: KI.
Investigation: KI TK TT.
Supervision: YI.
Writing – original draft: KI.
Writing – review & editing: KI.

**References**

1. Syvanen K, Korhonen P, Partanen A, Aarnio P. Endothelial function in a cardiovascular risk population with borderline ankle-brachial index. Vasc Health Risk Manag. 2011; 7: 97–101. doi: 10.2147/VHRM. S17249 PMID: 21415923
2. Matsuzawa Y, Guddeti RR, Kwon TG, Lerman LO, Lerman A. Secondary prevention strategy of cardiovascular disease using endothelial function testing. Circ J. 2015; 79: 685–694. doi: 10.1253/circj.CJ-15-0068 PMID: 25740088
3. Matsuzawa Y, Kwon TG, Lennon RJ, Lerman LO, Lerman A. Prognostic Value of Flow-Mediated Vasodilatation in Brachial Artery and Fingertip Artery for Cardiovascular Events: A Systematic Review and Meta-Analysis. J Am Heart Assoc. 2015; 4: e002270. doi: 10.1161/JAHA.115.002270 PMID: 26567372
4. Vita JA. Endothelial function. Circulation. 2011; 124: e906–e912. doi: 10.1161/CIRCULATIONAHA. 111.078824 PMID: 22184047
5. Bonetti PO, Pumper GM, Higano ST, Holmes DR Jr, Kuvin JT, Lerman A. Non-invasive identification of patients with early coronary atherosclerosis by assessment of digital reactive hyperemia. J Am Coll Cardiol. 2004; 44: 2137–2141. doi: 10.1016/j.jacc.2004.08.062 PMID: 15582310
6. Celermajer DS. Reliable endothelial function testing: at our fingertips? Circulation. 2008; 117: 2428–2430. doi: 10.1161/CIRCULATIONAHA.108.775155 PMID: 18474821
7. Poredos P, Jezovnik MK. Testing endothelial function and its clinical relevance. J Atheroscler Thromb. 2013; 20: 1–8. PMID: 22972428
8. Brevetti G, Silvestro A, Di Giacomo S, Bucur R, Di Donato AM, Schiavo V, et al. Endothelial dysfunction in peripheral arterial disease is related to increase in plasma markers of inflammation and severity of peripheral circulatory impairment but not to classic risk factors and atherosclerotic burden. J Vasc Surg. 2003; 38: 374–379. PMID: 12891123
9. Boos CJ, Balakrishnan B, Blann AD, Lip GY. The relationship of circulating endothelial cells to plasma indices of endothelial damage/dysfunction and apoptosis in acute coronary syndromes: implications for prognosis. J Thromb Haemost. 2008; 6: 1841–1850. doi: 10.1111/j.1538-7836.2008.03148.x PMID: 18761720

10. Martin FA, Murphy RP, Cummins PM. Thrombomodulin and the vascular endothelium: insights into functional, regulatory, and therapeutic aspects. Am J Physiol Heart Circ Physiol. 2013; 304: H1585–H1597. doi: 10.1152/ajpheart.00096.2013 PMID: 23604713

11. Blann AD, Seigneur M, Steiner M, Boisseau MR, McCollum CN. Circulating endothelial cell markers in peripheral vascular disease: relationship to the location and extent of atherosclerotic disease. Eur J Clin Invest. 1997; 27: 916–921. PMID: 9395787

12. Salomaa V, Matei C, Aleksic N, Sansores-Garcia L, Folsom AR, Juneja H, et al. Cross-sectional association of soluble thrombomodulin with mild peripheral artery disease; the ARIC study. Atherosclerosis. 2001; 157: 309–314. PMID: 11472730

13. Sernau T, Wilhelm C, Seyfert U, Gabath S, Henkels M, Amiral J, et al. Thrombomodulin is a marker of microvascular, but not for macrovascular endothelial cell damage. Vasa. 1995; 24: 347–353. PMID: 8533445

14. Kuvin JT, Patel AR, Sliney KA, Pandian NG, Schnell RI, Pumper GM, Kuvin JT, et al. Enhanced external counterpulsation improves endothelial function in patients with symptomatic coronary artery disease. J Am Coll Cardiol. 2003; 41: 1761–1768. PMID: 12767662

15. Nasser M, Wolosker N, Unt L, Rosoky RA, Lobato M, Wajngarten M, et al. Relationship between soluble thrombomodulin in patients with intermittent claudication and critical ischemia. Thromb Res. 2006; 117: 271–277. doi: 10.1016/j.thromres.2005.03.010 PMID: 15890390

16. Page AV, Liles WC. Biomarkers of endothelial activation/dysfunction in infectious diseases. Virulence. 2013; 4: 507–516. doi: 10.4161/viru.24530 PMID: 23669075

17. Levi M, Van Der Poll T. Thrombomodulin in sepsis. Minerva Anestesiol. 2013; 79: 294–298. PMID: 23241735

18. Hagag AA, Abdel-Lateef AE, Aly R. Prognostic value of plasma levels of thrombomodulin and von Willibrand factor in Egyptian children with acute lymphoblastic leukemia. J Oncol Pharm Pract. 2014; 20: 356–361. doi: 10.1177/1078155213508439 PMID: 24243921

19. Suessenbacher A, Dorler J, Wanitschek M, Alber HF, Pachinger O, Frick M. Prognostic value of peripheral arterial tonometry in patients with coronary artery disease and a high cardiovascular risk profile. J Atheroscler Thromb. 2014; 21: 230–238. PMID: 24140729

20. Blann AD, Farrell A, Picton A, McCollum CN. Relationship between endothelial cell markers and arterial stenosis in peripheral and carotid artery disease. Thromb Res. 2000; 97: 209–216. PMID: 10674407

21. Wang KC, Li YH, Shi GY, Tsai HW, Luo CY, Cheng MH, et al. Membrane-Bound Thrombomodulin Regulates Macrophage Inflammation in Abdominal Aortic Aneurysm. Arterioscler Thromb Vasc Biol. 2015; 35: 2412–2422. doi: 10.1161/ATVBAHA.115.305529 PMID: 26338301

22. Seigneur M, Dufourcq P, Conri C, Constans J, Moecie P, Pruvoart A, et al. Levels of plasma thrombomodulin are increased in atheromatous arterial disease. Thromb Res. 1993; 71: 423–431. PMID: 8134903

23. Bao YS, Jia XB, Wang D, Liu RC, Zou CB, Na SP. Characterization of soluble thrombomodulin levels in patients with stage 3–5 chronic kidney disease. Biomarkers. 2014; 19: 275–280. doi: 10.3109/1354750X.2014.94000 PMID: 24854597

24. Blann AD, Lip GYH, Beevers DG, McCollum CN. Soluble P-selectin in atherosclerosis: a comparison with endothelial cell and platelet markers. Thromb Haemost. 1997; 77: 1077–1080.

25. Babat S, Keller C, Kempe HP, Amiral J, Ziegler R, Ritz E, et al. Plasma thrombomodulin: a marker for microvascular complication in diabetes mellitus. Vasa. 1996; 25: 233–241. PMID: 8795304